I am fairly certain that the partner prospect that left MNKD at the alter a few years ago was a top 10 pharma. I believe this because why else would mnkd have been interested in partnering so early in the processs. I asked Matt Pfeffer about a year ago whether that same prospect was still considered a potential partner and he said "yes". As long as I'm speculating I'll add that the reason I think they are having difficulty inking a partner deal now is the extremely wide range of potential value based on multiple trials. Not just type I and II, but also superiority vs non-inferiority, and then of course labeling. There are billions of $ of sales at stake.